Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.
暂无分享,去创建一个
Junshik Hong | J. Lee | Sung-Soo Yoon | Y. Koh | Inho Kim | Gyeong-Won Lee | J. Byun | Junghoon Shin | D. Kim | Ki Hwan Kim | Yong Park | Y. Do | W. Kim | Yoon Seok Choi
[1] D. Longo,et al. Mantle-Cell Lymphoma. , 2022, The New England journal of medicine.
[2] Michael L. Wang,et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. , 2021, Blood advances.
[3] Michael L. Wang,et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.
[4] C. Visco,et al. Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy , 2020, British journal of haematology.
[5] Michael L. Wang,et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma , 2019, Leukemia.
[6] E. Kimby,et al. 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau , 2016, British journal of haematology.
[7] R. Advani,et al. Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.
[8] F. Cavalli,et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.
[9] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[10] G. Pizzolo,et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Salles,et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.
[12] W. Hiddemann,et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study , 2009, Leukemia & lymphoma.
[13] W. Hiddemann,et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma , 2007, Leukemia.
[14] J. Leonard,et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.